This content is in French.
Trastuzumab Deruxtecan: a new hope for HER2-mutated triple-negative breast cancers without HER2 expression
12 octobre 2025
By Lila Rouland | Published on October 12, 2025 | 3 min readThe HER2 receptor (ERBB2) is a transmembrane protein with tyrosine kinase activity, involved in cell proliferation, tumor invasion, and angiogenesis. Its overexpression has historically been associated with a poor prognosis in breast cancer. HER2-targeted therapies, such as trastuzumab and its antibody-drug conjugates (ADCs), have profoun
The HER2 receptor (ERBB2) is a transmembrane protein with tyrosine kinase activity, involved in cell proliferation, tumor invasion, and angiogenesis. Its overexpression has historically been associated with a poor prognosis in breast cancer. HER2-targeted therapies, such as trastuzumab and its antibody-drug conjugates (ADCs), have profoundly changed the management of HER2-positive patients.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Idamakanti M, et al. Long Durable Response With Trastuzumab Deruxtecan Monotherapy in a Triple-Negative Metastatic Breast Cancer Patient With Human Epidermal Growth Factor Receptor 2 Mutation[…]. J Med Cases. 2025;16(6):212-221.
View the source
